1
 
WELCOME
2
THIRD
GLOBAL INDIAN ENTREPRENEURS
CONFERENCE, NEW YORK, September, 12-15th, 2002
3
THIRD GLOBAL INDIAN ENTREPRENEURS CONFERENCE
Opportunities in Nanotechnology and
Biotechnology
4
Enormous Power A Simple Use! ?
5
(No Transcript)
6
Definition Any tecnique, product or process
which uses or is derived by using any living
system ( plant, animal or microoragnism ), to
make or modify a product, to improve plants or
animals , to develop micro-organisms for
specific use.
7
AREAS OF ACTIVITY
BIOTECHNOLOGY
http//www.accessexcellence.org/AB/GG/biotechnolog
y.html
8


Global Biotech



3 Billion
Global Biotech 250 Billion. Bio Drugs 25
Billion
Sunday, April 21, 2002 IITOL Special Report
http//www.ey.com/GLOBAL/gcr.nsf/International/Bio
tech_Interview_Forum_-_Healthcare_-_Ernst__Young




9
Biotechnology- Global Promise

• The global biotechnology industry consists of
  approximately 1,500 companies with industry
  revenues of USD 18 billion and a market
  capitalization exceeding USD 300 billion (1999
  figures)
• The global biotechnology industry is expected to
  grow to USD 400 billion by year 2005
• USFDA has approved 90 biotech products and over
  2,200 products are in development

10
Bangalore Bio 2002 15-17th April 56
Exhibitors 300 Conference Delegates 12,000
Business Visitors 24, 000 general Visitors
11
The India Advantage

• India offers significant advantages for research
  in biotechnology
• Vast pool of talented and skilled man power
• Several leading research institutions
• Large and diverse gene pool - plant and human
• Vast and naïve patient population essential for
  new drug development
• Lower operational costs and technologies
• English as the accepted business language
• Complementary competencies in BT and IT making
  India well positioned to exploit the Bio
  informatics wave

12
Biotechnology in India

• Biotechnology in India at a nascent stage
• Industry size estimated at US 3 billion (2002)
• Total biotech product market expected to grow 20
  /year
• The Indian biotech industry employs about 10,000
  people this number is expected to grow to 20,000
  by 2002

13
http//www.pharmabiz.com/specials/BioAsia/BioAsia1
.asp
14
Biotech market in India, m 2000 2005
Animal health-care products    
Vaccines 150 300
Antibiotics 225 275
Other 200 350
Agricultural products - -
High-yielding genetically modified seeds 450 650
Other 100 200
Industrial products - -
Industrial enzymes 50 100
Amino acids, organic acids 150 200
Yeast and yeast products 150 250
Total 1,475 2,325
Source Biocon India Forecast Forecast
15
COMPANY PRODUCTS
Avesthagen Technologies Plant genomics, GM Rice, Contract Research
Bangalore Genei Restriction enzymes, plasmids, bacterial host strains, gel documentation systems etc.
Bharat Biotech Hep B Vaccine, GCSF, Interferon, Streptokinase
Biocon India Enzymes, Lepuridine, Gamma Interferon, GCSF, Streptokinase, Human Insulin, Monoclonal antibodies.
Clinigene International Human genomics, Bioinformatics Contract Clinical Research
Dr Reddy's(DRL) GCSF, Interferon
Genotypic Technologies Array based HTS contract research
Lotus Labs Clinical trials Contract research
MAHYCO GM seeds Bt Cotton
Panacea Biotech Hep B Vaccine, Interferon, GCSF
Pro-Agro Seeds GM Crops, Bt cotton
Photonics Biomolecules Laser based diagnostics
Reliance Industries Stem cell research
Strand Genomics Bioinformatics based contract research services
Synegene International Disease Targets, r-DNA proteins, animal cell tissue culture Contract Research
Syngenta GM seeds
Wockhardt Hep B Vaccine, EPO, GCSF, Human Insulin
X-Cyton Recombinant diagnostics for AIDS, Hep C etc.
16
Growth areas for India

• - Biogenerics
• - Contract research
• - Contract manufacturing
• - Clinical trials
• - Genomics

• Bio-informatics
• Diagnostics
• Drug discovery and
• Novel drug delivery systems.

17
Biotechnology - Future Technology

• Biotechnology is a highly specialized segment of
  the life sciences industry
• Benefits range from product development in
  pharmaceuticals and healthcare, sustainable
  agriculture to solving problems of land and water
  pollution
• Growing global population putting tremendous
  pressure on large pharmaceutical companies for
  innovative new drugs
• Biotechnology industry seen as a key growth
  driver for the pharmaceutical industry

18
Future Treatment
19
Plant Biotechnology
20
(No Transcript)
21
Hope we have a lot ahead So close, but behind. So
dear, but with fear ! Nope, we cant turn
back But to march ahead!
22
Thanks ! for your coperation in sharing
information
Namastae !
The greatness in me is a reflection of Greatness
in you !
23
Srinivasa K. Rao, Ph.D., Chief, Bussiness
Technology Development.
SHANTHA BIOTECHNICS
Post Box No. 40137,Glen Oaks. NEW YORK,
11005 Tel [phone] Res 718 347
9070 Email srao_at_shanthabiotech.com
SHANTHA GROUP Shantha Biotechnics Pvt. Ltd.
Hyderabad, India Shantha Marine, Chennai,
India Shantha West Inc, San Diego, USA